For example, compelling evidence suggests that HER2 targeted therapy is highly effective in the treatment of HER2-positive breast cancer, but the responses are discordant, leading to overuse of HER2 monoclonal antibodies in non-responders which carry more risks than benefits. Here, ERBB2 is linked to breast cancer.